Granulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guérin therapy: Case report
© Gao et al; licensee BioMed Central Ltd. 2011
Received: 1 June 2011
Accepted: 30 September 2011
Published: 30 September 2011
Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the treatment of choice for superficial bladder carcinoma. Complications of BCG therapy include local infections and disseminated BCG infection with multiple endorgan complications.
We report a case of disseminated, post-treatment BCG infection that initially presented with granulomatous hepatitis and choroiditis. After successful anti-mycobacterial therapy and resolution of the hepatic and ocular abnormalities, the patient developed an acute upper gastrointestinal hemorrhage from an aortoduodenal fistula that required emergency surgery. The resection specimen revealed multifocal, non-caseating granulomas, indicating mycobacterial involvement.
This case highlights the varied end organ complications of disseminated BCG infection, and the need for vigilance even in immuno-competent patients with a history of intravesical BCG treatment.
Bacillus Calmette-Guérin (BCG) is a live, attenuated strain of the bovine tuberculosis bacillus, Mycobacterium bovis. Immunotherapy of neoplastic disease with BCG was developed in the 1960s and has been used for multiple neoplasms including malignant melanoma and acute lymphoblastic leukemia. In 1976, Morales et al. were the first to use intravesical BCG instillation to treat superficial bladder cancer . Since then, BCG therapy has become the treatment of choice for early stage transitional cell carcinoma of the bladder, with response rates ranging from 60%-94% - higher than any chemotherapeutic agent .
Although the virulence of attenuated BCG is low, serious and potentially life-threatening infections can occur even in the immunocompetent host. Adverse effects of BCG immunotherapy develop in 3-5% of patients . They include local complications such as bacterial cystitis, bladder contractures, granulomatous prostatitis, epididymitis, orchitis, and systemic reactions such as fever, malaise, hepatitis, and pneumonitis. Disseminated BCG infections presenting as pneumonitis or granulomatous hepatitis, are rare: in the largest retrospective study reported to date, dissemination occurred in 0.7% of over 2,000 patients . Ocular BCG manifestations include uveitis, endophthalmitis, and rarely choroiditis [5, 6]. The mechanism of BCG-related choroiditis is unclear - it may be due to a hypersensitivity response or to direct choroidal seeding by the bacteria. Vascular complications of BCG infection are well-known, and include infection and primary aortoenteric fistualization [7, 8].
We present a case of Mycobacterium bovis hepatitis and choroiditis occurring in an immunocompetent host more than one year after intravesical BCG treatment for bladder cancer. Following prolonged antimycobacterial therapy, the patient developed an aortoduodenal fistula that required emergency surgery and prompted a repeat course of antibiotics. To our knowledge, this constellation of end-organ complications of systemic, BCG infection has not previously been reported.
The patient had no history of immunodeficiencies. He had been diagnosed with superficial transitional cell carcinoma (TCC) of the bladder (Stage T1 with invasion into the lamina propria) in 2007. His initial treatment consisted of cystoscopic fulguration of the tumor. However, follow-up examinations revealed a local recurrence. Intravesical immunotherapy with weekly instillations of BCG (150 mg lyophilized Pasteur strain) was administered for a total of 6 weeks, starting in May, 2007. No immediate complications or traumatic instillations were reported.
On further laboratory testing, the patient's alkaline phosphatase level rose to and peaked at 1100 IU/L (Figure 1). This was associated with mild increase in transaminases (AST 56 IU/L, ALT 60 IU/L). On physical exam, the patient was anicteric. Tender hepatomegaly was present. Aerobic and anaerobic bacterial blood cultures were negative, as was a PCR serum assay for cytomegalovirus. The patient was admitted to the hospital for further workup.
Triple anti-mycobacterial therapy was initiated consisting of rifampin (600 mg daily), isoniazid (300 mg daily), and ethambutol (1200 mg daily) for a total of 12 months. On treatment, the patient regained his prior weight, and his physical exam and liver tests normalized (Figure 1). On ophthalmologic examination, the previously noted choroidal lesions had faded. The visual acuity remained unchanged. A follow-up liver biopsy was performed after the completion of anti-mycobacterial therapy. Scattered Langerhans cells were still present, but repeat PCR testing for Mycobacterium bovis was now negative.
Two months after the completion of anti-mycobacterial therapy, the patient presented to our hospital with an acute upper gastrointestinal hemorrhage. Emergency endoscopy revealed an adherent clot in the third portion of the duodenum. Abdominal CT examination revealed a previously documented abdominal aortic aneurysm. Compared to a study from one year prior, the diameter of the aneurysm had increased from 2.8 cm in the prior year to 4.1 cm and the aneurysm was impinging upon the third portion of the duodenum (Figure 5). The patient underwent emergency laparotomy, where an aortoduodenal fistualization with fresh clots was encountered. Aortic reconstruction and primary fistula repair were performed successfully. The surgical specimen was sent for pathologic and microbiological studies. Histological examination revealed multifocal, non-caseating granulomas with multinucleated giant cells (Figure 5). Special stains for AFB and fungal organisms were negative. In light of the patient's history of disseminated BCG infection and the presence of multiple granulomas on histological examination, it was felt that the patient warranted retreatment for Mycobacterium bovis. He was started on a repeat course of rifampin, isoniazid ethambutol and pyridoxine/B6. The patient is tolerating his treatment well and is currently asymptomatic.
Bacillus Calmette-Guérin (BCG) is an attenuated strain of the tuberculosis bacillus, Mycobacterium bovis. BCG induces an intense, localized inflammatory response upon instillation into the bladder. Its therapeutic mechanism of action is thought to involve the ingestion of viable mycobacteria by urothelial cells, which triggers a cytokine-mediated inflammatory response that results in the destruction of tumor cells.
Since its introduction in the 1970s, intravesical BCG treatment has been an effective treatment option of superficial bladder cancer, with a favorable safety profile and typically localized and self-limited side effect . However, systemic complications can occur. They include granulomatous involvement of lung (pneumonititis), liver (hepatitis), and bone marrow . Ophthalmologic and vascular complications have also been described but are considered extremely rare.
According to our literature review, the combination of granulomatous hepatitis, pneumonitis, choroiditis and aorto-enteric fistulization due to disseminated Mycobacterium bovis infection has not previously been reported. Our patient was initially referred for a hepatologic evaluation. His liver biopsy demonstrated the typical features of granulomatous hepatitis with numerous epitheloid noncaseating granulomas with intralobar distribution. Despite the negative acid fast stain, a high level of suspicion for mycobacterial infection resulted in further testing and the eventual establishment of multiorgan involvement with Mycobacterium bovis BCG. While hepatic, bone marrow, and pulmonary involvement have been extensively documented, the occurrence of mycobacterial choroiditis has only been reported in one prior case report . In this study, a 57 year-old patient developed bilateral ocular lesions that resembled those observed in our patient, following a 6-month course with intravesical BCG with the Connaught strain. Similar to our patient, his choroidal lesions did not progress after therapy with rifampin, isoniazid, and ethambutol .
Similarly, the development of an aortoenteric fistula due to disseminated BCG infection is a rare occurrence, with less than 20 cases documented in the literature . The proposed mechanisms of fistulization include hematogenous route via the vasa vasorum or local extension and lymphatic spread [7, 9].
Our case highlights the importance of considering unusual complications of BCG therapy and of appropriately monitoring patients at risk.
The proposed mechanisms of liver damage by BCG include direct infection as well as hypersensitivity reactions . In 1996, Leebeek demonstrated the presence of Mycobacterium bovis in liver tissues by PCR amplification . This finding supported the concept of hematogenous dissemination and direct tissue damage to the liver [11, 12]. However, the beneficial effect of adding corticosteroids to the antituberculous agents and the striking eosinophilic infiltration of the liver suggest that hypersensitivity reactions may also play a role [12, 13].. The absence of necrosis in the granulomas has been interpreted as additional evidence of a hypersensitivity reaction. However, hepatic granuloma may resemble those seen in miliary tuberculosis, in which necrosis is usually absent, rather than the caseating lesions of primary tuberculosis with liver involvement. With respect to establishing a diagnosis, our case highlights the limitations of AFB staining and conventional mycobacterial culture. Acid-fast stains are positive in only 10 percent of cases with hepatic involvement, possible due to the fact that a minimum of 10,000 organisms per gram of tissue are necessary to result in a positive stain . Mycobacterial cultures for the detection of BCG lack sensitivity and require a minimum of six to eight weeks of incubation. Molecular assays, including PCR-based tests, have superior sensitivity. However, even they may fail due to the paucity of organisms .
With respect to treatment, the recommended first line therapy for severe systemic BCG infection is the administration of isoniazid, rifampin and ethambutol. Treatment with pyrazinamide is not recommended since all known strains of Mycobacterium bovis are pyrazinamide-resistant . Adjunctive therapy with corticosteroids has been advocated by some authors. This recommendation is based on data from animal models and anecdotal clinical reports suggesting that corticosteroids improve the histological outcomes and treatment responses. However, corticosteroid should not be given without concomitant antimycobacterial coverage since they might increase the risk of systemic infection. With respect to prophylactic anti-mycobacterial treatment, the concomitant administration of BCG and antitubercular drugs has been advocated. However, this approach may result in drug-induced hepatitis and reduce the antitumor effects of BCG. Futhermore, systemic BCG infections can occur despite antibiotic prophylaxis.
In summary, we present an unusual case of multi-organ involvement with systemic mycobacterial infection following intravesical BCG treatment of bladder cancer in an immunocompetent patient. The constellation of granulomatous hepatitis, choroiditis and aortoduodenal fistula with gastrointestinal hemorrhage has not been previously reported . Our patient's course highlights the importance of recognizing potential risks from BCG treatment - even months after completion of treatment and in the absence of a history of immunodeficiencies - and of addressing its wide range of end-organ complications.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors acknowledge Heidi Heintz-Sailer for her assistance with the preparation of this manuscript.
- Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976, 116: 180-PubMedGoogle Scholar
- Oosterlinck W, van der Meijden A, Sylvestere R, et al: Guidelines on TaT1 bladder cancer. European Association of Urology Guidelines. 2006, Arnhem (The Netherlands): European Association of Urology, 1-17.Google Scholar
- Koga H, Kuroda M, Kudo S, et al: Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol. 2005, 12: 145-51. 10.1111/j.1442-2042.2005.01000.x.View ArticlePubMedGoogle Scholar
- Lamm DL, Van der Merjden PM, Morales A, et al: Incidence and treatment of complications bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992, 147: 596-600.PubMedGoogle Scholar
- Garip A, Diedrichs-Mohring M, Thurau SR, Deeg CA, Wildner G: Uveitis in a patient treat wih Bacille-Calmette-Guerin. Ophthalmology. 2009, 116: 2457-62. 10.1016/j.ophtha.2009.05.021.View ArticlePubMedGoogle Scholar
- Guex-Crosier Y, Charmot L, Zografos L: Chorioretinitis induced by intravesical Bacillus Calmette-Guerin (BCG) instillations for urinary bladder carcinoma. Klin Monbl Augenheilkd. 2003, 220 (3): 193-5. 10.1055/s-2003-38179.View ArticlePubMedGoogle Scholar
- Harding GEJ, Lawlor DK: Ruptured mycotic abdominal aortic aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guerin. J Vasc Surg. 2007, 46 (1): 131-4. 10.1016/j.jvs.2007.01.054.View ArticlePubMedGoogle Scholar
- Farber A, Grigoryants V, Palac D, Chapman T, et al: Primary aortoduodenal fistula in a patient with a history of intravesical therapy for bladder cancer with acillus Calmette-Guerin: Review of primary aortoduodenal fistula without abdominal aortic aneurysm. J Vasc Surg. 2001, 33 (4): 868-73. 10.1067/mva.2001.112327.View ArticlePubMedGoogle Scholar
- Coscas R, Jean-Benoit A, Belhomme D, et al: Multiple mycotic aneurysms due to Mycobacterium bovis after intravesical bacillus Calmette-Guerin therapy. J Vasc Surg. 2009, 50: 1185-90. 10.1016/j.jvs.2009.06.004.View ArticlePubMedGoogle Scholar
- Proctor DD, Chopra S, Rubenstein SC, Jokela JA, Uhl L: Mycobacteremia and granulomatous hepatitis following initial intravesical Bacillus Calmette-Guerin instillation for bladder cancer. Am J Gastroenterol. 1993, 88: 1112-1115.PubMedGoogle Scholar
- Leebeek FWG, Ouwendijk RJT, Kolk AHJ, et al: Granulomatous hepatitis caused by bacillus Calmette-Guerin (BCG0 infection after BCG bladder instillation. Gut. 1996, 38: 616-8. 10.1136/gut.38.4.616.View ArticlePubMedPubMed CentralGoogle Scholar
- Scully R, Mark EJ, Mcneely WF, Ebeling SH: Case records of the Massachusetts General Hospital, Case 29-1998. NEJM. 1998, 339 (12): 831-7. 10.1056/NEJM199809173391209.View ArticleGoogle Scholar
- DeHaven JI, Traynellis C, Riggs DR, Ting E, Lamm DL: Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. J Urol. 1992, 147: 738-42.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/11/260/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.